Tuesday, Addex Therapeutics Ltd (NASDAQ:ADXN) stock is trading higher with a session volume of 3.79 million versus the average volume of 4.16K as per data from Benzinga Pro.
Addex Therapeutics and Indivior PLC (NASDAQ:INDV) announced that they have selected clinical candidates from their GABAB-positive allosteric modulator (PAM) research collaboration.
Indivior has selected a compound for future development in substance use disorder and will now undertake all future development of their selected compound.
Under the terms of the agreement, Addex is eligible for payment of up to $330 million on achievement of prespecified regulatory, clinical and commercial milestones as well as tiered royalties on the level of net sales from high single digits up to low double-digit.
Under the terms of the agreement, Addex has also exercised its right to select a compound to advance its own independent GABAB PAM program for chronic cough.
"Indivior's collaboration with Addex has been instrumental in identifying a possible candidate for the treatment of substance use disorders," said Christian Heidbreder, Chief Scientific Officer at Indivior."
"The selection of GABAB PAM clinical candidates is the culmination of more than five years of research at Addex in close collaboration with the team at Indivior...We look forward to the next steps in the development of the substance use disorder program under the control of Indivior," said Tim Dyer, CEO of Addex. "On the Addex side, we are now focused on advancing our selected clinical candidate for chronic cough into IND-enabling studies."
In July, Addex Therapeutics announced that its partner Janssen Pharmaceuticals, Inc., a unit of Johnson & Johnson (NYSE:JNJ), discontinued the development of ADX71149 (JNJ-40411813) in epilepsy.
The decision follows top-line Phase 2 data announced in April, showing that adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam did not achieve statistical significance for the primary endpoint of time for patients to reach baseline seizure count when ADX71149 was added to standard of care.
星期二,Addex Therapeutics股票(NASDAQ:ADXN)的交易量较平均交易量0.416万高,达到379万,据Benzinga Pro数据。
Addex Therapeutics和Indivior PLC(NASDAQ:INDV)宣布,他们已从他们的GABAb阳性变构调节剂(PAM)研究合作中选出了临床候选药物。
Indivior已为将来的物质使用障碍开发选择了一种化合物,并将对其选择的化合物进行一切未来的开发工作。
根据协议条款,Addex有资格获得最高3.3亿元的预先指定的法规、临床和商业里程碑上的支付,以及根据净销售额的层级获得分层版税,从高个位数到低两位数。
根据协议的条款,Addex还行使了自己选择一个化合物来推进自己独立的GABAb PAm慢性咳嗽项目的权利。
“Indivior与Addex的合作在发现可能用于物质使用障碍治疗的候选药物方面起到了关键作用,”Indivior首席科学官Christian Heidbreder说。
“在与Indivior团队进行了五年多的密切合作后,GABAb PAm临床候选药物的选择是Addex研究的顶点...我们期待着根据Indivior的控制下推动物质使用障碍项目的下一步,”Addex首席执行官Tim Dyer表示。“在Addex方面,我们现在专注于推进我们选择的慢性咳嗽临床候选药物进入IND准备研究。”
七月,Addex Therapeutics宣布,其合作伙伴强生制药公司 (Johnson & Johnson旗下单位,纽交所:JNJ)在癫痫治疗中终止了ADX71149 (JNJ-40411813)的开发。
该决定是基于4月份宣布的2期临床试验的初步数据,该数据显示,在具有局灶性发作癫痫并对左乙拉西坦或布利脲酯反应不良的患者中,辅助使用ADX71149(JNJ-40411813)与标准治疗相比,无法达到统计学意义上的主要终点,即患者达到基线癫痫发作次数所需时间。
价格走势:截至周二最后一次查询,ADXN股票在盘前交易中上涨63.2%,报12.50美元。